Activation of PKCα isoform is known to be related to RPE proliferation and inhibition of PKCα has been considered as a potential therapeutic option for proliferative vitreoretinopathies (PVR) [18]. Here, PRKCA is linked to CAPN5-related vitreoretinopathy.